Table 3.
Rationality of prophylactic-antibiotic selection
| Group 1*, n (%) | Group2**, n (%) | P-value | ||
|---|---|---|---|---|
| Timing | 0–48 hours | 35 (7.87%) | 405 (94.19%) | <0.001 |
| >48 hours | 121 (92.14%) | 25 (5.71%) | ||
| Selection | Ceftriaxone | 156 (35.06%) | 74 (17.21%) | 0 |
| Ciprofloxacin | 3 (0.67%) | 0 | ||
| Metronidazole | 203 (45.62%) | 92 (21.40%) | ||
| Cefazolin | 16 (3.60%) | 264 (61.39%) | ||
| Vancomycin | 19 (4.27%) | 0 | ||
| Imipenem | 27 (6.07%) | 0 | ||
| Clindamycin | 3 (0.67%) | 0 | ||
| Meropenem | 3 (0.67%) | 0 | ||
| Ampibactam | 12 (2.70%) | 0 | ||
| Teicoplanin | 3 (0.67%) | 0 | ||
| Appropriateness | 134 (30.11%) | 393 (91.40%) | <0.001 | |
Notes: *Preintervention group; **postintervention group.